Home › Graft-Versus-Host Disease › Massachusetts
Graft-Versus-Host Disease clinical trials in Massachusetts
10 studies for Graft-Versus-Host Disease are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- Massachusetts General Hospital, Boston
Recruiting
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06910969Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 2 and older · All sexes · Updated Jul 23, 2026 · NCT06991361A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 16, 2026 · NCT04710576A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06615050Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
- Boston Children's Hospital, Boston
RecruitingPhase 2
Ages 2 and older · All sexes · Updated May 11, 2026 · NCT04380740Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Mar 11, 2026 · NCT05236062A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
- Dana Farber, Boston
RecruitingObservational study
36 Months · All sexes · Updated Oct 20, 2025 · NCT05866302IS-free Treg HaploHCT
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Oct 20, 2025 · NCT04678401Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.